High dose pharmaceutical grade biotin, MD1003, treatment preserves motor performance in a model of progressive neurodegeneration

被引：0
|
作者：
Nessler, S. [1 ]
Winkler, A. [1 ]
van der Meer, F. [1 ]
Gargareta, S. [1 ]
Cobos, A. [1 ]
Stadelmann, C. [1 ]
Nave, K. A. [2 ]
Brueck, W. [1 ]
机构：
[1] Univ Med Gottingen, Inst Neuropathol, Gottingen, Germany
[2] Max Planck Inst Expt Med, Dept Neurogenet, Gottingen, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P638
引用
收藏
页码：311 / 311
页数：1
相关论文
共 47 条
  • [41] MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
    Tourbah, Ayman
    Gout, Olivier
    Vighetto, Alain
    Deburghgraeve, Veronique
    Pelletier, Jean
    Papeix, Caroline
    Lebrun-Frenay, Christine
    Labauge, Pierre
    Brassat, David
    Toosy, Ahmed
    Laplaud, David-Axel
    Outteryck, Olivier
    Moreau, Thibault
    Debouverie, Marc
    Clavelou, Pierre
    Heinzlef, Olivier
    De Seze, Jerme
    Defer, Gilles
    Sedel, Frederic
    Arndt, Carl
    [J]. CNS DRUGS, 2018, 32 (07) : 661 - 672
  • [42] Improvement in the composite endpoint of timed 25 foot walk, maximum walking distance, or EDSS in a cohort of patients from the MD1003 (high dose pharmaceutical-grade biotin) in the French Early Access Program
    Tourbah, A.
    Faure, J.
    Carreau, C.
    Legrain, P.
    Castex, C.
    Caucheteux, N.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 530 - 530
  • [43] Effect of MD1003 (high doses of Biotin) in progressive multiple sclerosis: results of a pivotal phase III randomised double-blind placebo controlled study
    Tourbah, A.
    Lebrun-Frenay, C.
    Edan, G.
    Clanet, M.
    Papeix, A. -C.
    Vukusic, S.
    de Seze, J.
    Debouverie, M.
    Gout, O.
    Clavelou, P.
    Defer, G. L.
    Laplaud, D.
    Moreau, T.
    Labauge, P.
    Brochet, B.
    Sedel, M. M. F.
    Pelletier, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 49 - 49
  • [44] Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Cree, Bruce A. C.
    Cutter, Gary
    Wolinsky, Jerry S.
    Freedman, Mark S.
    Comi, Giancarlo
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Arnold, Douglas
    Kuhle, Jens
    Block, Valerie
    Munschauer, Frederick E.
    Sedel, Frederic
    Lublin, Fred D.
    [J]. LANCET NEUROLOGY, 2020, 19 (12): : 988 - 997
  • [45] 24-Month-Treatment with-MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of the MS-SPI Trial Extension Phase
    Tourbah, Ayman
    Lebrun-Frenay, Christine
    Edan, Gilles
    Clane, Michel
    Papeix, Caroline
    Vukusic, Sandra
    De Seze, Jerome
    Debouverie, Marc
    Gout, Olivier
    Clavelou, Pierre
    Defer, Gilles
    Laplaud, David
    Moreau, Thibault
    Labauge, Pierre
    Brochet, Bruno
    Sedel, Frederic
    Pelletier, Jean
    [J]. NEUROLOGY, 2016, 86
  • [46] Pharmaceutical-Grade High-Dose Biotin improves outcome in Non-active Progressive Multiple Sclerosis: Phase 3 placebo-controlled results
    Lasser, Robert
    Bendarraz, Abdelkarim
    Sedel, Frederic
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : NP12 - NP12
  • [47] EDSS and Timed 25 Foot Walk Correlate with Spinal Cord Areas: Baseline Results from the SPI2 Clinical Trial of MD-1003 (high-dose biotin) in Progressive Multiple Sclerosis
    Block, Valerie J.
    Alexander, Amber M.
    Papinutto, Nico
    Rajesh, Anand
    Gundel, Tristan
    Arnold, Douglas
    Sedel, Frederic
    Cree, Bruce
    Henry, Roland G.
    [J]. NEUROLOGY, 2019, 92 (15)
12345